Item 5. Market for Registrant’s Common Equity
Item 5. Market for Registrant’s Common Equity, Related Stoc kholder Matters, and Issuer Purchases of Equity Securities
Market Information for Common Stock
Our common stock is listed on The Nasdaq Global Market under the symbol “STRO.”
Holders of Record
As of March 20, 2024, there were approximately 69 stockholders of record of our common stock. The actual number of stockholders is greater than this number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.
Dividend Policy
We currently intend to retain future earnings, if any, for use in the operation of our business and to fund future growth. We have never declared or paid any cash dividends on our capital stock and do not anticipate paying any cash dividends in the foreseeable future. Payment of cash dividends, if any, in the future will be at the discretion of our Board of Directors and will depend on then-existing conditions, including our financial condition, operating results, contractual restrictions, capital requirements, business prospects and other factors our Board of Directors may deem relevant.
101
Stock Performance Graph
The following graph shows the total stockholder’s return on an initial investment of $100 in cash at market close on September 27, 2018 (the first day of trading of our common stock), through December 31, 2023 for (i) our common stock, (ii) the Nasdaq Composite Index and (iii) the Nasdaq Biotechnology Index. Pursuant to applicable Securities and Exchange Commission rules, all values assume reinvestment of pre-tax amount of all dividends; however, no dividends have been declared on our common stock to date. The stockholder return shown on the graph below is not necessarily indicative of or intended to forecast future performance, and we do not make or endorse any predictions as to future stockholder return.
This graph shall not be deemed “soliciting material” or be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 as amended, or Exchange Act, or otherwise subject to the liabilities under that Section, and shall not be deemed to be incorporated by reference into any of our filings under the Securities Act of 1933, as amended, or Securities Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.
102
Trade Date
Sutro
Biopharma
(STRO)
Nasdaq
Composite
Index (IXIC)
Nasdaq
Biotech
Index (^NBI)
9/27/2018
100.00
100.00
100.00
12/31/2018
59.34
82.51
79.47
3/29/2019
74.93
96.11
91.71
6/28/2019
74.87
99.56
89.51
9/30/2019
59.80
99.47
81.67
12/31/2019
72.37
111.57
98.87
3/31/2020
67.11
95.75
88.57
6/30/2020
51.05
125.08
112.21
9/30/2020
66.12
138.87
111.15
12/31/2020
142.83
160.26
124.26
3/31/2021
149.74
164.72
123.37
6/30/2021
122.30
180.35
134.42
9/30/2021
124.28
179.66
132.78
12/31/2021
97.89
194.54
123.48
3/31/2022
54.08
176.83
108.78
6/30/2022
34.28
137.14
97.88
9/30/2022
36.51
131.51
98.37
12/31/2022
53.16
130.15
110.01
3/31/2023
30.39
151.98
107.71
6/30/2023
30.59
171.45
106.45
9/30/2023
22.83
164.38
103.23
12/31/2023
28.22
186.66
114.12
The information required by this Item regarding equity compensation plans is incorporated by reference to the information set forth in Part III Item 12 of this Annual Report on Form 10-K.
Unregistered Sales of Equity Securities
None.
Purchases of Equity Securities by the Issuer and Affiliated Purchasers
None.
Item 6. [Reserved]
103